Sign In
Buy BAX
$19.35
+0.81 (+4.37%)
At Close: Jun 04, 2026
My Pink Slip Picks: 3 CEOs That Need to Be Fired
01:46pm, Tuesday, 23'rd Apr 2024
It's been a month since Boeing (NYSE: BA ) CEO Dave Calhoun announced that he would step down at the end of 2024. While his departure wasn't termed a “firing,” there is no question Calhoun's name
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
08:00am, Tuesday, 23'rd Apr 2024
SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two dec
Equity Investing Is About The Way Things Are, Not The Way Things Should Be
01:00pm, Monday, 22'nd Apr 2024
Rob Isbitts discusses navigating market risk and why the easy money era is over. Investors need to focus on both offense and defense in their portfolio strategy.
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
12:01pm, Friday, 12'th Apr 2024
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
10:36am, Thursday, 11'th Apr 2024
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
08:30am, Thursday, 11'th Apr 2024
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfo
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
04:15pm, Wednesday, 10'th Apr 2024
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 202
Reasons to Hold Baxter International (BAX) in Your Portfolio
01:01pm, Wednesday, 10'th Apr 2024
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
01:11pm, Tuesday, 02'nd Apr 2024
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
10 Coiled Spring Blue-Chip Bargain Buys
07:00am, Friday, 29'th Mar 2024
The market is near record highs and NVDA is up 11 straight weeks. Yet, blue-chip coiled spring bargains are still bountiful. VFLO is the best deep value strategy ETF I've found. A great combo of deep
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
04:15pm, Thursday, 29'th Feb 2024
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 20
Baxter International Inc. Is A Buy (Technical Analysis)
08:39pm, Monday, 26'th Feb 2024
Baxter International Inc. is a buy according to the analysis of price action, momentum, volume, and relative strength.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
01:11pm, Thursday, 08'th Feb 2024
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Baxter (BAX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Thursday, 08'th Feb 2024
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
09:41am, Thursday, 08'th Feb 2024
Baxter International (BAX) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago.
